Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
NCT03918408
Recruiting
To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
11/09/2024
Locations: Pacific Clear Vision Institute, Eugene, Oregon
Conditions: Keratoconus, Unstable, Bacterial Keratitis, Ectasia of Cornea
Register for Updates
Escitalopram and Language Intervention for Subacute Aphasia
NCT03843463
Recruiting
In this project, the investigators will investigate the effects of a selective serotonin reuptake inhibitor (SSRI), escitalopram, on augmenting language therapy effectiveness, as measured by naming untrained pictures and describing pictures, in individuals with aphasia in the acute and subacute post stroke period (i.e., within three months post stroke).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/08/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland +2 locations
Conditions: Aphasia, Stroke
Register for Updates
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
NCT04768972
Recruiting
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Gender:
ALL
Ages:
10 years and above
Trial Updated:
11/08/2024
Locations: University of California San Diego, La Jolla, California +24 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth
NCT05230004
Recruiting
An immediate fit adjustable prosthetic system is being investigated for children. The age range being recruited is from 3 years up to 18 years old. Phase I of this study will involve developing a final prototype by conducting in-lab testing on children with limb loss. Phase II will involve a two month home trial to further evaluate the comfort and usability of the socket. Outcome measures include a PEQ-based questionnaire, socket pressure measures and gait analysis.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
11/08/2024
Locations: Penn Medicine Rittenhouse, Philadelphia, Pennsylvania
Conditions: Limb Deficiencies, Pediatric ALL
Register for Updates
SV2A in Older Adults
NCT05465538
Recruiting
The aim of the study is to examine the effect of cannabis use on brain synaptic density among older adults using \[11C\]UCB-J PET imaging.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/08/2024
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Cannabis Use
Register for Updates
Testing of Online Version of QAPS
NCT05905523
Recruiting
Early evaluation of prewriting skills is important, as prewriting skills set the stage for later learning of the fine motor and visual motor skills needed for writing. Evaluation of prewriting skills allows for the identification of those children who struggle with these tasks so that early intervention might address these foundational skills before academic demands become more challenging. However, current prewriting skill assessments are limited to pencil-and-paper assessments that require an... Read More
Gender:
ALL
Ages:
Between 3 years and 7 years
Trial Updated:
11/08/2024
Locations: Virginia Commonweath University, Richmond, Virginia
Conditions: Child Development
Register for Updates
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06128044
Recruiting
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: The University of Alabama at Birmingham (UAB), Birmingham, Alabama +9 locations
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Overcontrol and Suicide in PTSD
NCT06355284
Recruiting
High standards and self-discipline are prized in military culture, but drawbacks of overcontrol are often ignored. Overcontrol is characterized by over-regulated behavior and cognitive rigidity, driven by an intense need for perfection and control. It is frequently observed in people with obsessive-compulsive (OC) spectrum disorders, especially OC Personality Disorder (OCPD). Their inclination to set high expectations for others can strain social bonds. When grappling with mental health challeng... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/08/2024
Locations: Providence VA Medical Center, Providence, RI, Providence, Rhode Island
Conditions: Compulsive Personality Disorder, Stress Disorders, Post-Traumatic
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Grandview Medical Group Research, LLC, Birmingham, Alabama +127 locations
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: University of Arizona, Tucson, Arizona +136 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
Association Between Gut Microbiome and Dietary Determinants and Vaccine Response
NCT05239403
Recruiting
This study evaluates the association between gut microbiome and dietary determinants and vaccine response. This study aims to learn if diet and the microbes (such as bacteria and viruses) found in your gut affect the body's immune response to the influenza vaccine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Influenza
Register for Updates
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
NCT05478707
Recruiting
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) and exercise training each enhance insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
11/08/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Diabetes Mellitus, Type 1, Endothelial Dysfunction
Register for Updates